Dr Tina Wang

Ting (Tina) Wang is Associate Director, HTA Programme and Strategic Partnerships at the Centre for Innovation in Regulatory Science (CIRS). Tina leads CIRS’ work on HTA strategy and research as part of the CIRS mission to advance regulatory and HTA policies and processes. Tina’s scope of responsibilities covers all aspects of HTA activities from concept through to delivery. These include project managing the CIRS HTA Programme and coordinating a HTA steering committee, executing and implementation of metrics studies evaluating the HTA processes within companies and agencies on annual basis, conducting independent literature research and designing specialised surveys.

Tina is also responsible for developing the CIRS HTA Programme research strategy, ensuring alignment between the overarching CIRS regulatory and HTA vision, and leading the strategic partnership with multi-stakeholders globally. Prior to joining CIRS in 2010, Tina worked as a research scientist at Medpharm and GlaxoSmithKline.

Tina received her undergraduate degree in Applied Chemistry from the Beijing University of Technology and a Master of Science in Pharmaceutical Analysis and Quality Control from Kings College, University of London. Tina completed her PhD at the WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University and her research is focused on “The evolution of HTA practice and approaches from the perspectives of HTA agencies and pharmaceutical industry”.

Tina is a member of longstanding international scientific societies such as Health Technology Assessment international (HTAi), and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at various international conferences. Tina’s main field of interest is international HTA policy and intelligence